article thumbnail

Gates, Wellcome-backed TB vaccine starts phase 3 trial

pharmaphorum

A highly anticipated phase 3 trial of a new tuberculosis vaccine developed by GSK has started in Africa, funded by the Gates MRI and Wellcome.

article thumbnail

Pfizer, after delay, completes enrollment in Lyme vaccine trial

Bio Pharma Dive

The announcement ends a lengthy setback that began when the company and partner Valneva accused a clinical trial site operator of study misconduct.

Trials 278
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nouscom extends Series C round to $82m for cancer vaccine trials

Pharmaceutical Technology

Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.

article thumbnail

MinervaX raises $57m for Phase III trial of maternal strep vaccine

Pharmaceutical Technology

MinervaX is currently conducting Phase II trials of the prophylactic maternal vaccine against group B streptococcus bacterial infections.

article thumbnail

Successful clinical trial for re-engineered Covid vaccine 

Drug Discovery World

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The Clamp2 trial group showed a 2.5-fold fold boost in neutralising ‘titres’ and it was 2.1 in the Novavax group.

article thumbnail

GSK sets high bar with trial results for RSV vaccine

Bio Pharma Dive

With data expected for several other vaccines for the respiratory disease, GSK reported positive clinical trial results showing efficacy above 80%.

article thumbnail

CMV Vaccine Trials: Moderna’s CMV mRNA Vaccine Enters Phase III

XTalks

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.